Skip to main content
QURE logo

QURE · uniQure N.V.

Track QURE — free
$48.62 +1.56 (+3.31%) At close · Aug 14
Market Cap
$3.07B
Shares
63.07M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$48.62 Open$47.06 Day$46.31–48.70 52W close$9.03–70.59 Avg vol 30d1.4M Short int10.7M · 16.9% float · 6.8d Short vol46% Last earningsJul 29, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Nov 1, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Jul 29, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 14.3 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +75%
      above
      Price vs 50-day avg +20%
      above
      RSI (14) 69
      neutral
      MACD trend Positive
      52-week position 64%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +21%
      trailing
      6-month return +99%
      trailing
      YTD return +103%
      this year
      Relative strength +85%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $41 › 200d $28 — 50d above 200d
      Institutional flow Accumulating
      +16% holders QoQ · +88 funds added
      Insider flow Distributing
      Net -$966.9K over 90 days · 100% sells
      Short interest Rising
      16.94% of float · ▲ +3.0% MoM · 6.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      257 holders — near 3-yr high, broad support
      Squeeze score 87
      high risk · 0–100
      Fundamentals
      Fair
      Revenue growth −48%
      Y/Y
      EPS growth +30%
      Y/Y
      Free cash flow $-178.4M
      Balance sheet $29.5M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 284%
      annualized · 1-yr
      Max drawdown −87%
      past year
      ATR 4.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Buy
      0 · 4 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +75% Bullish
      Price vs 50-day avg
      +20% Bullish
      RSI (14)
      69 Neutral
      MACD trend
      Positive Bullish
      52-week position
      64% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $41 › 200d $28 — 50d above 200d
      Institutional flow Accumulating
      +16% holders QoQ · +88 funds added
      Insider flow Distributing
      Net -$966.9K over 90 days · 100% sells
      Short interest Rising
      16.94% of float · ▲ +3.0% MoM · 6.8 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      257 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $9 Now $49 · 64% Range high $71
      vs 200-day avg +75% vs 50-day avg +20%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      QURE
      uniQure N.V.
      this stock
      $3.07B +103.2% -47.8% 16.9%
      ONC
      BeOne Medicines Ltd.
      $513.62B +14.4% +22179.2% 789.7 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      $128.19B +11.6% +46.2% 29.5 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      $82.72B +4.1% +20.8% 19.9 3.3%
      ARGX
      Argenx SE
      $52.94B +1.2% 2.1%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      257
      % held
      122.4%
      Net QoQ
      +1.2M sh
      Top holder
      Avoro Capital Advisors LLC
      Held Float
      View
      Held by Funds
      Fund positions
      17
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      10.7M
      Days to cover
      6.8d
      Change
      +315.7K sh
      View
      Short Volume
      Short vol %
      46%
      As of
      Aug 14, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      2
      Value
      $85
      As of
      Jul 13, 2026
      View
      Off-Exchange
      Off-exchange %
      42.3%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$966.9K
      Buyers / Sellers
      0 / 9
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $13.1M
      Net income (FY)
      $-199.0M
      EPS diluted
      $-3.46
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 29, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $951.9K
      Shares
      21.1K
      Filed
      Jul 2, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 29, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      QURE +4.7% +20.8% +98.7% +11.4% +103.2%
      SPY +0.4% +4.5% +13.8% +3.9% +13.9%
      vs SPY +4.3% +16.4% +85.0% +7.5% +89.3%
      Key facts CIK 1590560 CUSIP N90064101 13F (30d) 256 filings 248 filers Visit website Investor relations